Acute Intravenous Injection Toxicity Study of Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 in Rat

다국어 초록 (Multilingual Abstract)

Study Design: Prospective in vivo toxicity study.
Purpose: To evaluate the conducted acute toxicity study of Escherichia coli (E. coli )-derived recombinant human bone morphogenetic protein-2 (rhBMP-2) with 6-weeks old Sprague-Dawley rats.
Overview of Literature: rhBMP-2 has well-known osteoinductivity and it is used as a bone graft substitute. E. coli -derived rhBMP-2 can be mass-produced with relatively low costs. E. coli -derived rhBMP-2 facilitates osteoblastic differentiation and bone formation in vitro and in vivo . However, studies regarding side effects or toxicity of E. coli-derived rhBMP-2 have not been published. Thus, we conducted the acute toxicity study of E. coli -derived rhBMP-2 on 6-weeks old Sprague-Dawley rats.
Methods: One mg of BMP-2 was diluted in 0.285 mL of glycine buffer to prepare high BMP-2 concentrations (3.5 mg/mL). Intermediate (0.9 mg/mL) or low (0.35 mg/mL) concentrations of BMP-2 solution was prepared by serial dilutions. The compound was administrated at a dose of 0, 0.7, 1.8, 7 mg/kg by single intravenous injection to five of male and female rats. After the injection, the gross general observations including changes of body weight and histopathological analysis was performed for 14 days.
Results: No animal was found dead during the experiment and the body weight changes were both statistically insignificant in the control and experimental groups. No abnormal sign was shown in general observations and autopsy examinations.
Conclusions: Thus, the lethal dose of E. coli -derived rhBMP-2 should be higher than 7 mg/kg with a single intravenous injection.

참고문헌 (Reference)

1 Westerhuis RJ, "Use of bone morphogenetic proteins in traumatology" 36 : 1405-1412, 2005

2 Lee JH, "The short-term effects of repetitive E. coli-derived rhBMP-2 administration through intravenous injection in rats" 37 : 40-47, 2014

3 Poynton AR, "Safety profile for the clinical use of bone morphogenetic proteins in the spine" 27 (27): S40-S48, 2002

4 Anderson DW, "Postoperative cervical myelopathy and cord compression associated with the use of recombinant bone morphogenetic protein-2 in posterior cervical decompression, instrumentation, and arthrodesis: a report of two cases" 36 : E682-E686, 2011

5 Owens K, "Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion" 20 : 612-617, 2011

6 이재협, "Expression, Purification and Osteogenic Bioactivity of Recombinant Human BMP-2 Derived by Escherichia Coli" 한국조직공학과 재생의학회 8 (8): 8-15, 2011

7 Israel DI, "Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells" 7 : 139-150, 1992

8 Robin BN, "Cytokine-mediated inflammatory reaction following posterior cervical decompression and fusion associated with recombinant human bone morphogenetic protein-2: a case study" 35 : E1350-E1354, 2010

9 Smoljanovic T, "Could chronic host inflammatory response be responsible for delayed onset of retrograde ejaculation after the labeled use of recombinant human bone morphogenetic protein-2?" 11 : 167-168, 2011

10 Lee JH, "Comparative study of fusion rate induced by different dosages of Escherichia coli-derived recombinant human bone morphogenetic protein-2 using hydroxyapatite carrier" 12 : 239-248, 2012

11 Axelrad TW, "Bone morphogenetic proteins in orthopaedic surgery" 20 : 481-488, 2009

12 Carragee EJ, "A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned" 11 : 471-491, 2011

13 Benglis D, "A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery" 62 : ONS423-ONS431, 2008